We report a patient who developed significant liver dysfunction following therapy with terbinafine. At the end of a 31/2-wk course of terbinafine, he developed progressive jaundice and pruritus. His serum bilirubin peaked at 30.9 mg/dl 3 wk after discontinuing terbinafine. A liver biopsy revealed mild to moderate mixed cellular infiltrate in the portal tracts, and hepatocellular and canicular cholestasis. His liver tests normalized 100 days after stopping terbinafine.
Center for Liver Diseases and Transplantation and Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, California
*Center for Liver Diseases and Transplantation Cedars-Sinai Medical Center, 590 W 8635 West 3rd Street, Los Angeles, CA 90043.
